QHRD106 ameliorates ischemic stroke injury as a long-acting tissue kallikrein preparation

Si-Yi Xu,Jun-Qiu Jia,Min Sun,Xin-Yu Bao,Sheng-Nan Xia,Shu Shu,Pin-yi Liu,Sen-lin Ji,Lei Ye,Xiang Cao,Yun Xu
DOI: https://doi.org/10.1016/j.isci.2023.107268
IF: 5.8
2023-07-01
iScience
Abstract:Ischemic stroke is the second leading cause of death worldwide, and there are limited effective treatment strategies. QHRD106, a polyethyleneglycol (PEG)-modified long-acting tissue kallikrein preparation, has not been reported previously. In this study, we aimed to investigate the therapeutic effect of QHRD106 in ischemic stroke and its possible mechanism. We found that QHRD106 treatment alleviated brain injury after stroke via bradykinin (BK) receptor B2 (B2R) instead of BK receptor B1 (B1R). Mechanistically, QHRD106 reduced high-mobility group box 1 (HMGB1)-induced apoptosis and inflammation after ischemic stroke <i>in vivo</i> and <i>in vitro</i>. Moreover, we confirmed that QHRD106 reduced the level of acetylated HMGB1 and reduced the binding between heat shock protein 90 alpha family class A member 1 (HSP90AA1) and HMGB1, thus inhibiting the translocation and release of HMGB1. In summary, these findings indicate that QHRD106 treatment has therapeutic potential for cerebral ischemic stroke.
multidisciplinary sciences
What problem does this paper attempt to address?